Boehringer Ingelheim Corporation Release: New Study Showed Significant Reduction In Blood Glucose With Linagliptin Alone And In Combination With Metformin In Adults Newly Diagnosed With Type 2 Diabetes
Published: Dec 03, 2013
INGELHEIM, Germany & INDIANAPOLIS, US--(BUSINESS WIRE)--For Non-US and Non-UK Media. Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D). The result showed that linagliptin as monotherapy or in initial combination with metformin achieved clinically significant improvements in glucose control in patients with newly diagnosed T2D and marked hyperglycaemia. Results also showed both treatments provided statistically significant reductions in blood glucose levels, with the combination therapy having greater glucose reduction compared to monotherapy. The results were presented during the 2013 World Diabetes Congress, which is being held 2-6 December in Melbourne, Australia.
Help employers find you! Check out all the jobs and post your resume.